SlideShare a Scribd company logo
B-ALL MRD
Maryalice Stetler-Stevenson, M.D., Ph.D.
Flow Cytometry Unit, Laboratory of Pathology,
CCR, NCI, NIH
DEPARTMENT OF HEALTH & HUMAN SERVICES
National Instit
Bethesda, M
Public Health
FL1 FL2 FL4 FL5 FL6 FL8
FITC PE
Per CP-
Cy5.5
PC7 APC
APC-Cy7
or APC-H7
Tube 1
CD20 CD10 CD38* CD19 CD58 CD45*
B9E9 J5 HIT2 J3-119 N901 2D1
3ml 10ml 5ml 3ml 10ml 3ml
Tube 2
CD9
CD13/
CD33
CD34* CD19 CD10* CD45*
ALB6
SJ1D1
/D3HL60.2
51
8G12 J3-119 HI10a 2D1
3ml 5ml / 10ml 15ml 3ml 3ml 3ml
Tube 3
Syto-16 CD3* CD19 CD71* CD45*
S7578 SK7 J3-119 L10.1 2D1
1ml 10ml 3ml 5ml 3ml
The COG Assay Panel
The COG Gating Strategy for B-ALL MRD:
Time
FSC-A
0 12500 2500 0 37500 5 0000
0
65536
13 1072
19 6608
26 2144
Time 8color
CD19 PC7
SSC-A
10
2
10
3
10
4
10
5
0
65 536
131 072
196 608
262 144
FSC-A
SSC-A
0 65536 131072 1966 08 262144
0
65536
1310 72
1966 08
2621 44
CD45 AH7
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
FSC-A
FSC-H
0 65536 1 31072 196608 262 144
0
65536
131072
196608
262144
SINGLETS
Case 1
SF15 1185 bm_06_L-3.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF15 1185 bm_04_L-1.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF15 1185 bm_05_L-2.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF15 1185 bm_01_S-1.fcs Time 8color
FSC-A
FSC-H
0 6 5536 131072 196608 26214 4
0
6 5536
1 3107 2
1 9660 8
2 6214 4
SINGLETS
SF15 1185 7aad9_viability.fcs Viability Singlets
7AAD
SSC-A
10
2
10
3
10
4
10
5
0
65 536
1 310 72
1 966 08
2 621 44
7aad SSC Viable
7AAD
Gate % of
Gated
Cells
None 100
7aad SSC 97
SF15 1185 bm_01_S-1.fcs SINGLETS
FSC-A
SSC-A
0 65 536 131072 1966 08 26 2144
0
65536
1 3107 2
1 9660 8
2 6214 4
SF15 1185 bm_04_L-1.fcs SINGLETS
CD19 PC7
SSC-A
10
2
10
3
10
4
10
5
0
65536
131072
196608
262144
SF15 1185 bm_04_L-1.fcs 8c B CD19 PC7 SSC
CD45 AH7
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Clean L1 gate
SF15 1185 bm_05_L-2.fcs 8c B CD19 PC7 SSC
CD45 AH7
CD19PC7 10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Quadrant # of
Events
% of
Gated
Cells
% of
All
Cells
UL 90199 16.65 9.02
UR 613 0.11 0.06
LL 305369 56.37 30.54
LR 145532 26.87 14.55
Gate # of
Events
% of
Gated
Cells
% of
All
Cells
None 906160 100.00 90.62
Syto 16 positive 906160 100.00 90.62
Syto16 MNC 541713 59.78 54.17
Syto16 + Syto16 + MNC
Case 1
SF15 1185 bm_06_L-3.fcs
Syto 16 positive
Syto 16
SSC-A
10
2
10
3
10
4
10
5
0
65536
131072
196608
262144
Syto 16 positive
SF15 1185 bm_06_L-3.fcs
Syto16 MNC
CD3 PerCP
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5 16.65% 0.11%
56.37% 26.87%
SF15 1185 bm_06_L-3.fcs
Syto 16 positive
FSC-A
SSC-A
26 65556 131085 196615 262144
0
65536
1310 72
1966 08
2621 44
Syto16 MNC
SF15 1185 bm_06_L-3.fcs
Syto 16 positive
CD3 PerCP
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
16.55%73.09%
0.09%10.27%
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD19 PC7
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD10 PE
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD45 AH7
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD20 FITC
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Case 1
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD45 AH7
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD38 PerCP Cy55
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD20 FITC
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD45 AH7
CD20FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD20 FITC
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
L1 Plasma cells?
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD20 FITC
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Gate 1 L1
1.10%
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD45 AH7
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD38 PerCP Cy55
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD19 PC7
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_04_L-1.fcs Clean L1 gate
CD19 PC7
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Gate # of
Events
% of
Gated
Cells
% of
All
Cells
None 76867 100.00 7.69
8c B CD19 PC7 76867 100.00 7.69
Clean L1 gate 76867 100.00 7.69
Gate 1 L1 845 1.10 0.08
Case 1
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD19 PC7
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD9 FITC
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
% of L-22 Cells ALL=
% of L-22 MNC ALL=
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD34 PerCP Cy55
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD10 APC
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD45 AH7
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD34 PerCP Cy55
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD19 PC7
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD34 PerCP Cy55
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD13+33 PE
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD45 AH7
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD19 PC7
CD34PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD45 AH7
CD34PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD19 PC7
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5 Gate 2 L1
0.88%
SF15 1185 bm_05_L-2.fcs Clean L2 Gate
CD45 AH7
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Gate # of
Events
% of
Gated
Cells
% of
All
Cells
None 91625 100.00 9.16
8c B CD19 PC7 91625 100.00 9.16
Clean L2 Gate 91625 100.00 9.16
Gate 2 L1 806 0.88 0.08
Case 1
Tube 1:
845 x 90,199 x 100= 0.18
76,867 541,713
Tube 2:
806 x 90,199 x 100= 0.15
91,625 541,713
Case 2
SF15 657 7aad_viability.fcs
No Gate
Time
FSC-A
0 5000 10000 15000 20000
0
65536
131072
196608
262144
Time 4color
SF15 657 bm_07_L-3.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF15 657 bm_05_L-1.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF15 657 bm_06_L-2.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF15 657 bm_05_L-1.fcs 8c B CD19 PC7 SSC
CD45 AH7
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Clean L1 gate
SF15 657 bm_05_L-1.fcs SINGLETS
CD19 PC7
SSC-A
10
2
10
3
10
4
10
5
0
65536
131072
196608
262144
SF15 657 bm_01_S-1.fcs Time 8color
FSC-A
FSC-H
0 65536 131072 196608 262144
0
65536
131072
196608
262144
SINGLETS
SF15 657 bm_01_S-1.fcs Time 8color
FSC-A
FSC-W
0 65536 131072 196608 262144
0
65536
131072
196608
262144
SF15 657 7aad_viability.fcs Viability Singlets
7AAD
SSC-A
10
2
10
3
10
4
10
5
0
65536
131072
196608
262144
7AAD
7aad SSC Viable
Gate % of
Gated
Cells
None 100
7aad SSC 89
SF15 657 bm_01_S-1.fcs SINGLETS
FSC-A
SSC-A
0 65536 131072 196608 262144
0
65536
131072
196608
262144
Case 2
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD38 PerCP Cy55
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD20 FITC
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD10 PE
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD38 PerCP Cy55
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD45 AH7
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD45 AH7
CD20FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD45 AH7
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Gate 1 L1
2.55%
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD20 FITC
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD20 FITC
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Gate # of
Events
% of
Gated
Cells
% of
All
Cells
None 47182 100.00 4.72
8c B CD19 PC7 47182 100.00 4.72
Clean L1 gate 47182 100.00 4.72
Gate 1 L1 1205 2.55 0.12
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD20 FITC
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD19 PC7
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD19 PC7
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD19 PC7
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_05_L-1.fcs Clean L1 gate
CD45 AH7
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD10 APC
CD34PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD19 PC7
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Case 2
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD45 AH7
CD34PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD19 PC7
CD34PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD45 AH7
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Gate 1 L2
2.57%
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD34 PerCP Cy55
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD13+33 PE
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD34 PerCP Cy55
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD19 PC7
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD19 PC7
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Gate # of
Events
% of
Gated
Cells
% of
All
Cells
None 44447 100.00 4.44
Clean L2 44447 100.00 4.44
Gate 1 L2 1141 2.57 0.11
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD10 APC
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD19 PC7
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD10 APC
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 657 bm_06_L-2.fcs Clean L2 Gate
CD45 AH7
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Case 2
SF15 657 bm_07_L-3.fcs
Syto 16 positive
Syto 16
SSC-A
10
2
10
3
10
4
10
5
0
65 536
13 1 07 2
19 6 60 8
26 2 14 4
Syto 16 positive
SF15 657 bm_07_L-3.fcs
Syto16 MNC
CD3 PerCP
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
8.24%39.24%
0.09%52.43%
SF15 657 bm_07_L-3.fcs
Syto 16 positive
FSC-A
SSC-A
26 65556 131085 196615 262144
0
65536
1 31072
1 96608
2 62144
Syto16 MNC
SF15 657 bm_07_L-3.fcs
Syto 16 positive
CD3 PerCP
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5 5.75% 0.04%
91.58% 2.62%
Quadrant # of
Events
Y
Geometric
Mean
% of
Gated
Cells
% of
All
Cells
UL 43565 7998.77 52.43 4.36
UR 75 4515.68 0.09 0.01
LL 32601 0.00 39.24 3.26
LR 6848 0.00 8.24 0.68
Gate # of
Events
% of
Gated
Cells
% of
All
Cells
None 850029 100.00 85.00
Syto 16 positive 850029 100.00 85.00
Syto16 MNC 83089 9.77 8.31
Case 2
Tube 1:
1,205 x 43,565 x 100= 1.34
47,182 83,089
Tube 2:
1,141 x 43,565 x 100= 1.35
44,447 83,089
Case 3
SF15 2200 bm 7aad_viability.fcs
No Gate
Time
FSC-A
0 5000 10000 15000 20000
0
65536
131072
196608
262144
Time 4color
SF15 2200 bm_05_L-3.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF15 2200 bm_03_L-1.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF15 2200 bm_04_L-2.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF15 2200 bm_01_S-1.fcs Time 8color
FSC-A
FSC-H
0 65 536 131 072 19 660 8 2 62144
0
6 55 36
131 0 72
196 6 08
262 1 44
SINGLETS
SF15 2200 bm_01_S-1.fcs Time 8color
FSC-A
FSC-W
0 6 5 536 131 072 19 6608 2 62144
0
655 36
1310 7 2
1966 0 8
2621 4 4
SF15 2200 bm 7aad_viability.fcs Viability Singlets
7AAD
SSC-A
10
2
10
3
10
4
10
5
0
65 5 36
13 1 072
19 6 608
26 2 144
7aad SSC Viable
7AAD
Gate % of
Gated
Cells
None 100
7aad SSC 86
SF15 2200 bm_03_L-1.fcs 8c B CD19 PC7 SSC
CD45 AH7
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Clean L1 gate SF15 2200 bm_03_L-1.fcs SINGLETS
CD19 PC7
SSC-A
10
2
10
3
10
4
10
5
0
6553 6
1 310 7 2
1 966 0 8
2 621 4 4
Gate # of
Events
% of
Gated
Cells
% of
All
Cells
None 4735 100.00 0.55
8c B CD19 PC7 4735 100.00 0.55
Clean L1 gate 4735 100.00 0.55
Gate 1.L1 180 3.80 0.02
Case 3
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD45 AH7
CD20FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD20 FITC
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD20 FITC
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD20 FITC
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
L1 Plasma cells?
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD20 FITC
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD45 AH7
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD19 PC7
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD45 AH7
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD38 PerCP Cy55
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD45 AH7
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5 Gate 1.L1
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD10 PE
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD19 PC7
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD38 PerCP Cy55
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_03_L-1.fcs Clean L1 gate
CD19 PC7
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD45 AH7
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD19 PC7
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Case 3
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD19 PC7
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD10 APC
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD19 PC7
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD34 PerCP Cy55
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD9 FITC
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
% of L-22 Cells ALL=
% of L-22 MNC ALL=
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD45 AH7
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD34 PerCP Cy55
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD13+33 PE
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD34 PerCP Cy55
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD45 AH7
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD19 PC7
CD34PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2200 bm_04_L-2.fcs Clean L2 Gate
CD45 AH7
CD34PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Gate # of
Events
% of
Gated
Cells
% of
All
Cells
None 4485 100.00 0.57
8c B CD19 PC7 4485 100.00 0.57
Gate 1.L2 170 3.79 0.02
Clean L2 Gate 4485 100.00 0.57
Case 3
SF15 2200 bm_05_L-3.fcs
Syto16 MNC
CD3 PerCP
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5 6.10% 0.14%
64.89% 28.88%
SF15 2200 bm_05_L-3.fcs
Syto 16 positive
FSC-A
SSC-A
26 655 56 1 31 08 5 19 66 15 2 6214 4
0
65 53 6
1 31 072
1 96 608
2 62 144
Syto16 MNC
SF15 2200 bm_05_L-3.fcs
Syto 16 positive
CD3 PerCP
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
7.55%91.34%
0.44%0.68%
Quadrant # of
Events
% of
Gated
Cells
% of
All
Cells
UL 5335 6.10 0.53
UR 121 0.14 0.01
LL 56778 64.89 5.68
LR 25271 28.88 2.53
Gate # of
Events
% of
Gated
Cells
% of
All
Cells
None 826111 100.00 82.61
Syto 16 positive 826111 100.00 82.61
Syto16 MNC 87505 10.59 8.75
SF15 2200 bm_05_L-3.fcs
Syto 16 positive
Syto 16
SSC-A
10
2
10
3
10
4
10
5
0
65536
131072
196608
262144
Syto 16 positive
Case 3
Tube 1:
180 x 5,335 x 100= 0.23
4,735 87,505
Tube 2:
170 x 5,335 x 100= 0.23
4,485 87,505
Case 4
SF15 2455 7aad_viability.fcs
No Gate
Time
FSC-A
0 5000 10000 15000 20000
0
65536
131072
196608
262144
Time 4color
SF15 2455 bm_06_L-3.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF15 2455 bm_04_L-1.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF15 2455 bm_05_L-2.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF15 2455 bm_01_S-1.fcs Time 8color
FSC-A
FSC-H
0 65536 131072 196608 262144
0
65536
131072
196608
262144
SINGLETS
SF15 2455 bm_01_S-1.fcs Time 8color
FSC-A
FSC-W
0 65536 131072 196608 262144
0
65536
131072
196608
262144F15 2455 7aad_viability.fcs Viability Singlets
7AAD
SSC-A
10
2
10
3
10
4
10
5
0
65536
131072
196608
262144
7AAD
7aad SSC Viable
Gate % of
Gated
Cells
None 100
7aad SSC Viable 93
SF15 2455 bm_01_S-1.fcs SINGLETS
FSC-A
SSC-A
0 65536 131072 196608 262144
0
65536
131072
196608
262144
SF15 2455 bm_04_L-1.fcs 8c B CD19 PC7 SSC
CD45 AH7
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Clean L1 gate
SF15 2455 bm_04_L-1.fcs SINGLETS
CD19 PC7
SSC-A
10
2
10
3
10
4
10
5
0
65 536
131072
196608
262144
Case 4
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD19 PC7
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD20 FITC
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD20 FITC
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD20 FITC
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
L1 Plasma cells?
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD20 FITC
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD45 AH7
CD20FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD38 PerCP Cy55
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD10 PE
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD38 PerCP Cy55
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD45 AH7
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD19 PC7
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD45 AH7
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD19 PC7
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_04_L-1.fcs Clean L1 gate
CD45 AH7
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Gate # of
Events
% of
Gated
Cells
% of
All
Cells
None 3518 100.00 0.35
8c B CD19 PC7 3518 100.00 0.35
Clean L1 gate 3518 100.00 0.35
Gate 1.L1 1331 37.83 0.13
Case 4
Gate # of
Events
% of
Gated
Cells
% of
All
Cells
None 4582 100.00 0.46
8c B CD19 PC7 4582 100.00 0.46
Gate 1.L2 2557 55.81 0.26
Clean L2 Gate 4582 100.00 0.46
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD45 AH7
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD45 AH7
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD45 AH7
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD34 PerCP Cy55
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD19 PC7
CD34PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD45 AH7
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Gate 1.L2
55.81%
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD13+33 PE
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD34 PerCP Cy55
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD19 PC7
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD45 AH7
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD10 APC
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD34 PerCP Cy55
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD10 APC
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
% of L-22 Cells ALL=
% of L-22 MNC ALL=
SF15 2455 bm_05_L-2.fcs Clean L2 Gatee
CD19 PC7
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Case 4
SF15 2455 bm_06_L-3.fcs
Syto 16 positive
Syto 16
SSC-A
10
2
10
3
10
4
10
5
0
65536
131072
196608
262144
Syto 16 positive
SF15 2455 bm_06_L-3.fcs
Syto16 MNC
CD3 PerCP
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
16.59%81.40%
0.06%1.94%
SF15 2455 bm_06_L-3.fcs
Syto 16 positive
FSC-A
SSC-A
26 6 5556 13 1085 196615 262 144
0
655 36
131072
196608
262144
Syto16 MNC
SF15 2455 bm_06_L-3.fcs
Syto 16 positive
CD3 PerCP
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5 0.54% 0.09%
91.81% 7.57%
Quadrant # of
Events
% of
Gated
Cells
% of
All
Cells
UL 4588 1.94 0.46
UR 152 0.06 0.02
LL 192527 81.40 19.25
LR 39240 16.59 3.92
Gate # of
Events
% of
Gated
Cells
% of
All
Cells
None 877716 100.00 87.77
Syto 16 positive 877716 100.00 87.77
Syto16 MNC 236507 26.95 23.65
Case 4
Tube 1:
1331 x 4588 x 100= 0.73
3518 236507
Tube 2:
2557 x 4588 x 100= 1.1
4582 236507
Which tube had better isolation of ALL from Normal?
Case 5
SF16 043 7aad_viability.fcs
No Gate
Time
FSC-A
0 5000 10000 15000 20000
0
65536
131072
196608
262144
Time 4color
SF16 043 bm_06_L-3_003.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF16 043 bm_04_L-1_001.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF16 043 bm_05_L-2_002.fcs
No Gate
Time
FSC-A
0 12500 25000 37500 50000
0
65536
131072
196608
262144
Time 8color
SF16 043 bm_01_S-1_002.fcs Time 8color
FSC-A
FSC-H
0 65536 1310 72 19 6608 26214 4
0
65536
131072
196608
262144
SINGLETS
SF16 043 bm_01_S-1_002.fcs Time 8color
FSC-A
FSC-W
0 65536 1310 72 19 6608 2 62144
0
65536
131072
196608
262144F16 043 7aad_viability.fcs Viability Singlets
7AAD
SSC-A
10
2
10
3
10
4
10
5
0
65 536
13 107 2
19 660 8
26 214 4
7AAD
7aad SSC Viable
Gate % of
Gated
Cells
None 100
7aad SSC Viable 93
SF16 043 bm_01_S-1_002.fcs Time 8color
FSC-A
SSC-A
0 65536 13107 2 19 660 8 262 14 4
0
65 53 6
1 31 07 2
1 96 60 8
2 62 14 4
SF16 043 bm_04_L-1_001.fcs 8c B CD19 PC7 SSC
CD45 AH7
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Clean L1 gate
SF16 043 bm_04_L-1_001.fcs SINGLETS
CD19 PC7
SSC-A
10
2
10
3
10
4
10
5
0
65 536
131072
196608
262144
Case 5
SF16 043 bm_06_L-3_003.fcs
Syto 16 positive
Syto 16
SSC-A
10
2
10
3
10
4
10
5
0
65 536
131 072
196 608
262 144
Syto 16 positive
SF16 043 bm_06_L-3_003.fcs
Syto16 MNC
CD3 PerCP
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
25.93%44.99%
0.08%29.00%
SF16 043 bm_06_L-3_003.fcs
Syto 16 positive
FSC-A
SSC-A
26 65 556 13 10 8 5 1 9 6615 2 62 1 44
0
65 5 36
1 310 72
1 966 08
2 621 44
Syto16 MNC
SF16 043 bm_06_L-3_003.fcs
Syto 16 positive
CD3 PerCP
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5 5.91% 0.11%
86.68% 7.30%
Quadrant # of
Events
% of
Gated
Cells
% of
All
Cells
UL 47936 29.00 4.79
UR 140 0.08 0.01
LL 74375 44.99 7.44
LR 42872 25.93 4.29
Gate # of
Events
% of
Gated
Cells
% of
All
Cell
s
None 977423 100 98
Syto 16 positive 886478 91 89
Syto16 MNC 165323 17 17
Case 5
SF16 043 bm_04_L-1_001.fcs Clean L1 gate
CD20 FITC
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_04_L-1_001.fcs Clean L1 gate
CD20 FITC
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_04_L-1_001.fcs Clean L1 gate
CD20 FITC
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
L1 Plasma cells?
SF16 043 bm_04_L-1_001.fcs Clean L1 gate
CD20 FITC
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_04_L-1_001.fcs Clean L1 gate
CD45 AH7
CD20FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_04_L-1_001.fcs Clean L1 gate
CD19 PC7
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_04_L-1_001.fcs Clean L1 gate
CD38 PerCP Cy55
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_04_L-1_001.fcs Clean L1 gate
CD10 PE
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_04_L-1_001.fcs Gate 7
CD45 AH7
CD10PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_04_L-1_001.fcs Clean L1 gate
CD19 PC7
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_04_L-1_001.fcs Clean L1 gate
CD38 PerCP Cy55
CD19PC7
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_04_L-1_001.fcs Gate 7
CD45 AH7
CD38PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Gate 1.L1
2.08%
SF16 043 bm_04_L-1_001.fcs Clean L1 gate
CD19 PC7
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_04_L-1_001.fcs Clean L1 gate
CD45 AH7
CD58APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Gate # of
Events
% of
Gated
Cells
None 49767 100.00
8c B CD19 PC7 49767 100.00
Clean L1 gate 49767 100.00
Gate 1.L1 1111 2.23
SF16 043 bm_05_L-2_002.fcs Clean L2 Gate
CD45 AH7
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_05_L-2_002.fcs Clean L2 Gate
CD19 PC7
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_05_L-2_002.fcs Clean L2 Gate
CD45 AH7
CD34PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Case 5
L-2 9 13+33 34 19 10 45
SF16 043 bm_05_L-2_002.fcs Clean L2 Gate
CD19 PC7
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_05_L-2_002.fcs Gate 9
CD9 FITC
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
% of L-22 Cells ALL=
% of L-22 MNC ALL=
SF16 043 bm_05_L-2_002.fcs Clean L2 Gate
CD34 PerCP Cy55
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_05_L-2_002.fcs Clean L2 Gate
CD10 APC
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_05_L-2_002.fcs Clean L2 Gate
CD19 PC7
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_05_L-2_002.fcs Clean L2 Gate
CD45 AH7
CD9FITC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_05_L-2_002.fcs Clean L2 Gate
CD34 PerCP Cy55
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_05_L-2_002.fcs Clean L2 Gate
CD13+33 PE
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_05_L-2_002.fcs Clean L2 Gate
CD34 PerCP Cy55
CD10APC
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_05_L-2_002.fcs Clean L2 Gate
CD45 AH7
CD13+33PE
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
SF16 043 bm_05_L-2_002.fcs Clean L2 Gate
CD19 PC7
CD34PerCPCy55
10
2
10
3
10
4
10
5
10
2
10
3
10
4
10
5
Gate # of
Events
% of
Gated
Cells
% o
All
Cel
None 42549 100.00 4.2
8c B CD19 PC7 42549 100.00 4.2
Gate 1.L2 918 2.16 0.0
Clean L2 Gate 42549 100.00 4.2
Case 5
Tube 1:
1111 x 47936 x 100= 0.65
49767 165323
Tube 2:
918 x 47936 x 100= 0.63
42549 165323
Remember Typical Analysis Errors:
Miscalling hematogones
Overly tight gating, especially initial B cell gate
Lack of hierarchical gating
Artifacts and normal variants

More Related Content

What's hot

ONCOTRANS 2017 - Eric Raymond - TGF-beta inhibition
ONCOTRANS 2017 - Eric Raymond - TGF-beta inhibitionONCOTRANS 2017 - Eric Raymond - TGF-beta inhibition
ONCOTRANS 2017 - Eric Raymond - TGF-beta inhibition
Prof. Eric Raymond Oncologie Medicale
 
Noncoding RNAs in Cardiovascular Disease – Potential as Biomarkers and More
Noncoding RNAs in Cardiovascular Disease – Potential as Biomarkers and MoreNoncoding RNAs in Cardiovascular Disease – Potential as Biomarkers and More
Noncoding RNAs in Cardiovascular Disease – Potential as Biomarkers and More
QIAGEN
 
I psc and stem cell 2013
I psc and stem cell 2013I psc and stem cell 2013
I psc and stem cell 2013Elsa von Licy
 
NSCLC: diagnóstico molecular, pronóstico y seguimiento; CTC
NSCLC: diagnóstico molecular, pronóstico y seguimiento; CTCNSCLC: diagnóstico molecular, pronóstico y seguimiento; CTC
NSCLC: diagnóstico molecular, pronóstico y seguimiento; CTC
Mauricio Lema
 
Rare Mutation Analysis Using Digital PCR on QuantStudio™ 3D to Verify Ion Amp...
Rare Mutation Analysis Using Digital PCR on QuantStudio™ 3D to Verify Ion Amp...Rare Mutation Analysis Using Digital PCR on QuantStudio™ 3D to Verify Ion Amp...
Rare Mutation Analysis Using Digital PCR on QuantStudio™ 3D to Verify Ion Amp...
Thermo Fisher Scientific
 
The clinical application development and validation of cell free dna assays -...
The clinical application development and validation of cell free dna assays -...The clinical application development and validation of cell free dna assays -...
The clinical application development and validation of cell free dna assays -...
Candy Smellie
 
Diagnóstico funcional y genético de las inmunodeficiencias primarias
Diagnóstico funcional y genético de las inmunodeficiencias primariasDiagnóstico funcional y genético de las inmunodeficiencias primarias
Diagnóstico funcional y genético de las inmunodeficiencias primarias
Vall d'Hebron Institute of Research (VHIR)
 
miRNA profiling from blood challenges and recommendations - Download the article
miRNA profiling from blood challenges and recommendations - Download the articlemiRNA profiling from blood challenges and recommendations - Download the article
miRNA profiling from blood challenges and recommendations - Download the article
QIAGEN
 
Epi tect methylation qpcr arrays 2013
Epi tect methylation qpcr arrays 2013Epi tect methylation qpcr arrays 2013
Epi tect methylation qpcr arrays 2013Elsa von Licy
 
Cacoub Manif Extra HéPatiques
Cacoub Manif Extra HéPatiquesCacoub Manif Extra HéPatiques
Cacoub Manif Extra HéPatiquesodeckmyn
 
Defining the relevant genome in solid tumors
Defining the relevant genome in solid tumorsDefining the relevant genome in solid tumors
Defining the relevant genome in solid tumors
Thermo Fisher Scientific
 
Innovación en terapia sistémica de cáncer de pulmón
Innovación en terapia sistémica de cáncer de pulmónInnovación en terapia sistémica de cáncer de pulmón
Innovación en terapia sistémica de cáncer de pulmón
Mauricio Lema
 
Fibrosis and wound healing 2013
Fibrosis and wound healing 2013Fibrosis and wound healing 2013
Fibrosis and wound healing 2013Elsa von Licy
 
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...
QIAGEN
 
1073957 wp rt2_profilerapp_1012
1073957 wp rt2_profilerapp_10121073957 wp rt2_profilerapp_1012
1073957 wp rt2_profilerapp_1012Elsa von Licy
 
Rabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_ForumRabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_Forum
EAFO1
 
Successful detection of 40 COSMIC hotspot mutations at allelic frequency belo...
Successful detection of 40 COSMIC hotspot mutations at allelic frequency belo...Successful detection of 40 COSMIC hotspot mutations at allelic frequency belo...
Successful detection of 40 COSMIC hotspot mutations at allelic frequency belo...
Thermo Fisher Scientific
 
Hcv Meh Cacoub
Hcv Meh CacoubHcv Meh Cacoub
Hcv Meh Cacoubodeckmyn
 

What's hot (20)

ONCOTRANS 2017 - Eric Raymond - TGF-beta inhibition
ONCOTRANS 2017 - Eric Raymond - TGF-beta inhibitionONCOTRANS 2017 - Eric Raymond - TGF-beta inhibition
ONCOTRANS 2017 - Eric Raymond - TGF-beta inhibition
 
Pp adna epi_tect
Pp adna epi_tectPp adna epi_tect
Pp adna epi_tect
 
Noncoding RNAs in Cardiovascular Disease – Potential as Biomarkers and More
Noncoding RNAs in Cardiovascular Disease – Potential as Biomarkers and MoreNoncoding RNAs in Cardiovascular Disease – Potential as Biomarkers and More
Noncoding RNAs in Cardiovascular Disease – Potential as Biomarkers and More
 
I psc and stem cell 2013
I psc and stem cell 2013I psc and stem cell 2013
I psc and stem cell 2013
 
NSCLC: diagnóstico molecular, pronóstico y seguimiento; CTC
NSCLC: diagnóstico molecular, pronóstico y seguimiento; CTCNSCLC: diagnóstico molecular, pronóstico y seguimiento; CTC
NSCLC: diagnóstico molecular, pronóstico y seguimiento; CTC
 
Rare Mutation Analysis Using Digital PCR on QuantStudio™ 3D to Verify Ion Amp...
Rare Mutation Analysis Using Digital PCR on QuantStudio™ 3D to Verify Ion Amp...Rare Mutation Analysis Using Digital PCR on QuantStudio™ 3D to Verify Ion Amp...
Rare Mutation Analysis Using Digital PCR on QuantStudio™ 3D to Verify Ion Amp...
 
The clinical application development and validation of cell free dna assays -...
The clinical application development and validation of cell free dna assays -...The clinical application development and validation of cell free dna assays -...
The clinical application development and validation of cell free dna assays -...
 
Diagnóstico funcional y genético de las inmunodeficiencias primarias
Diagnóstico funcional y genético de las inmunodeficiencias primariasDiagnóstico funcional y genético de las inmunodeficiencias primarias
Diagnóstico funcional y genético de las inmunodeficiencias primarias
 
miRNA profiling from blood challenges and recommendations - Download the article
miRNA profiling from blood challenges and recommendations - Download the articlemiRNA profiling from blood challenges and recommendations - Download the article
miRNA profiling from blood challenges and recommendations - Download the article
 
Epi tect methylation qpcr arrays 2013
Epi tect methylation qpcr arrays 2013Epi tect methylation qpcr arrays 2013
Epi tect methylation qpcr arrays 2013
 
Cacoub Manif Extra HéPatiques
Cacoub Manif Extra HéPatiquesCacoub Manif Extra HéPatiques
Cacoub Manif Extra HéPatiques
 
Defining the relevant genome in solid tumors
Defining the relevant genome in solid tumorsDefining the relevant genome in solid tumors
Defining the relevant genome in solid tumors
 
Innovación en terapia sistémica de cáncer de pulmón
Innovación en terapia sistémica de cáncer de pulmónInnovación en terapia sistémica de cáncer de pulmón
Innovación en terapia sistémica de cáncer de pulmón
 
Epigenetics 2013
Epigenetics 2013Epigenetics 2013
Epigenetics 2013
 
Fibrosis and wound healing 2013
Fibrosis and wound healing 2013Fibrosis and wound healing 2013
Fibrosis and wound healing 2013
 
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...
 
1073957 wp rt2_profilerapp_1012
1073957 wp rt2_profilerapp_10121073957 wp rt2_profilerapp_1012
1073957 wp rt2_profilerapp_1012
 
Rabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_ForumRabade_Nikhil_V_Hematology_Forum
Rabade_Nikhil_V_Hematology_Forum
 
Successful detection of 40 COSMIC hotspot mutations at allelic frequency belo...
Successful detection of 40 COSMIC hotspot mutations at allelic frequency belo...Successful detection of 40 COSMIC hotspot mutations at allelic frequency belo...
Successful detection of 40 COSMIC hotspot mutations at allelic frequency belo...
 
Hcv Meh Cacoub
Hcv Meh CacoubHcv Meh Cacoub
Hcv Meh Cacoub
 

Viewers also liked

Affordable housing in Cavite rush rush for sale/brand new houses rush for sal...
Affordable housing in Cavite rush rush for sale/brand new houses rush for sal...Affordable housing in Cavite rush rush for sale/brand new houses rush for sal...
Affordable housing in Cavite rush rush for sale/brand new houses rush for sal...
Cavitehousesrushforsale Inhouse
 
Pelan tindakan internship
Pelan tindakan internshipPelan tindakan internship
Pelan tindakan internshipRashadah Hj Isa
 
Actividad: Animales
Actividad: AnimalesActividad: Animales
Actividad: Animales
Victoria Llns Bd
 
alexis
alexisalexis
alexis
juan alvarez
 
1520 S. Trumbull Final Pro-forma -R.M
1520 S. Trumbull Final Pro-forma -R.M1520 S. Trumbull Final Pro-forma -R.M
1520 S. Trumbull Final Pro-forma -R.MMicheal Grandieson
 
Resilient Design Management
Resilient Design ManagementResilient Design Management
Resilient Design Management
Chris Avore
 
Estratégias para Otimização de Consultas do Hibernate em uma Aplicação Web
Estratégias para Otimização de Consultas do Hibernate em uma Aplicação WebEstratégias para Otimização de Consultas do Hibernate em uma Aplicação Web
Estratégias para Otimização de Consultas do Hibernate em uma Aplicação Web
Allan Silva
 
Non violencia contra as mulleres
Non violencia contra as mulleresNon violencia contra as mulleres
Non violencia contra as mulleres
Marisé Roca Garcia
 
Ten-Color, 14 Antibody Flow cytometry (FCM) Screening Tube for Lymphoprolifer...
Ten-Color, 14 Antibody Flow cytometry (FCM) Screening Tube for Lymphoprolifer...Ten-Color, 14 Antibody Flow cytometry (FCM) Screening Tube for Lymphoprolifer...
Ten-Color, 14 Antibody Flow cytometry (FCM) Screening Tube for Lymphoprolifer...
RajabAmr
 
SCREENING TUBEs_ICCS_2016-AR
SCREENING TUBEs_ICCS_2016-ARSCREENING TUBEs_ICCS_2016-AR
SCREENING TUBEs_ICCS_2016-ARAmr Rajab
 
Resume_Rakesh_SAP MM-SRM
Resume_Rakesh_SAP MM-SRMResume_Rakesh_SAP MM-SRM
Resume_Rakesh_SAP MM-SRMRakesh Ranjan
 
A Guide to Fine Dining
A Guide to Fine DiningA Guide to Fine Dining
A Guide to Fine Dining
Bob Asken
 
Studio f
Studio fStudio f
Studio f
Gustavo Agudelo
 
Förpackningsdesign
FörpackningsdesignFörpackningsdesign
Förpackningsdesignsanei172
 
Ansible + Hadoop
Ansible + HadoopAnsible + Hadoop
Ansible + Hadoop
Michael Young
 
Introduction to Flow Cytometry
Introduction to Flow CytometryIntroduction to Flow Cytometry
Introduction to Flow Cytometry
Robert (Rob) Salomon
 
The Role of the Insulation System in Optimizing value in LNG Facilities
The Role of the Insulation System in Optimizing value in LNG FacilitiesThe Role of the Insulation System in Optimizing value in LNG Facilities
The Role of the Insulation System in Optimizing value in LNG Facilities
Joe Hughes
 

Viewers also liked (19)

Affordable housing in Cavite rush rush for sale/brand new houses rush for sal...
Affordable housing in Cavite rush rush for sale/brand new houses rush for sal...Affordable housing in Cavite rush rush for sale/brand new houses rush for sal...
Affordable housing in Cavite rush rush for sale/brand new houses rush for sal...
 
Pelan tindakan internship
Pelan tindakan internshipPelan tindakan internship
Pelan tindakan internship
 
Actividad: Animales
Actividad: AnimalesActividad: Animales
Actividad: Animales
 
SPAWAR_Pocket_Guide
SPAWAR_Pocket_GuideSPAWAR_Pocket_Guide
SPAWAR_Pocket_Guide
 
alexis
alexisalexis
alexis
 
1520 S. Trumbull Final Pro-forma -R.M
1520 S. Trumbull Final Pro-forma -R.M1520 S. Trumbull Final Pro-forma -R.M
1520 S. Trumbull Final Pro-forma -R.M
 
Resilient Design Management
Resilient Design ManagementResilient Design Management
Resilient Design Management
 
Estratégias para Otimização de Consultas do Hibernate em uma Aplicação Web
Estratégias para Otimização de Consultas do Hibernate em uma Aplicação WebEstratégias para Otimização de Consultas do Hibernate em uma Aplicação Web
Estratégias para Otimização de Consultas do Hibernate em uma Aplicação Web
 
Non violencia contra as mulleres
Non violencia contra as mulleresNon violencia contra as mulleres
Non violencia contra as mulleres
 
Ten-Color, 14 Antibody Flow cytometry (FCM) Screening Tube for Lymphoprolifer...
Ten-Color, 14 Antibody Flow cytometry (FCM) Screening Tube for Lymphoprolifer...Ten-Color, 14 Antibody Flow cytometry (FCM) Screening Tube for Lymphoprolifer...
Ten-Color, 14 Antibody Flow cytometry (FCM) Screening Tube for Lymphoprolifer...
 
SCREENING TUBEs_ICCS_2016-AR
SCREENING TUBEs_ICCS_2016-ARSCREENING TUBEs_ICCS_2016-AR
SCREENING TUBEs_ICCS_2016-AR
 
Resume_Rakesh_SAP MM-SRM
Resume_Rakesh_SAP MM-SRMResume_Rakesh_SAP MM-SRM
Resume_Rakesh_SAP MM-SRM
 
Semiotics final
Semiotics finalSemiotics final
Semiotics final
 
A Guide to Fine Dining
A Guide to Fine DiningA Guide to Fine Dining
A Guide to Fine Dining
 
Studio f
Studio fStudio f
Studio f
 
Förpackningsdesign
FörpackningsdesignFörpackningsdesign
Förpackningsdesign
 
Ansible + Hadoop
Ansible + HadoopAnsible + Hadoop
Ansible + Hadoop
 
Introduction to Flow Cytometry
Introduction to Flow CytometryIntroduction to Flow Cytometry
Introduction to Flow Cytometry
 
The Role of the Insulation System in Optimizing value in LNG Facilities
The Role of the Insulation System in Optimizing value in LNG FacilitiesThe Role of the Insulation System in Optimizing value in LNG Facilities
The Role of the Insulation System in Optimizing value in LNG Facilities
 

Similar to Dr. maryalice stetler stevenson all mrd

Introduction to electrical distribution and control components
Introduction to electrical distribution and control componentsIntroduction to electrical distribution and control components
Introduction to electrical distribution and control components
CTY TNHH HẠO PHƯƠNG
 
ONEAL+OCM550.pdf
ONEAL+OCM550.pdfONEAL+OCM550.pdf
ONEAL+OCM550.pdf
Paulo Henrique S
 
Ciclotron dynamic 12000 h 2ω
Ciclotron   dynamic 12000 h 2ωCiclotron   dynamic 12000 h 2ω
Ciclotron dynamic 12000 h 2ωMuniz Rodrigues
 
OptiCal & LUMOS Networks
OptiCal & LUMOS NetworksOptiCal & LUMOS Networks
OptiCal & LUMOS Networks
Tal Lavian Ph.D.
 
diagrama del modulo y sensores.pdf
diagrama del modulo y sensores.pdfdiagrama del modulo y sensores.pdf
diagrama del modulo y sensores.pdf
pitechu
 
Sua chua may lanh cua daikin
Sua chua may lanh cua daikinSua chua may lanh cua daikin
Sua chua may lanh cua daikin
suadiennuochanoi.vn
 
Diagrama de Tarjeta T-Con
Diagrama de Tarjeta T-ConDiagrama de Tarjeta T-Con
Diagrama de Tarjeta T-Con
Carlos Quiroga
 
Arduino mega-schematic
Arduino mega-schematicArduino mega-schematic
Arduino mega-schematic
Jose Gomez
 
Edu ciaa-nxp pinout-a4_v4r3_es
Edu ciaa-nxp pinout-a4_v4r3_esEdu ciaa-nxp pinout-a4_v4r3_es
Edu ciaa-nxp pinout-a4_v4r3_es
Juan Barón
 
ECS H77H2-M4 rA.pptx
ECS H77H2-M4 rA.pptxECS H77H2-M4 rA.pptx
ECS H77H2-M4 rA.pptx
ssusercda6b5
 
LG CRT TV MODEL Ct 21q92ke
LG CRT TV MODEL Ct 21q92keLG CRT TV MODEL Ct 21q92ke
LG CRT TV MODEL Ct 21q92ke
Malik Arif
 
Bn44 00645 a+40f5300
Bn44 00645 a+40f5300Bn44 00645 a+40f5300
Bn44 00645 a+40f5300
jorge patarroyo fletcher
 
Antibody validation
Antibody validationAntibody validation
Antibody validation
Fridtjof Lund-Johansen
 
SI47XX_Tuner (1).pdf
SI47XX_Tuner (1).pdfSI47XX_Tuner (1).pdf
SI47XX_Tuner (1).pdf
dedysuryadi10
 
Tabela trans smd
Tabela trans smdTabela trans smd
Tabela trans smd
Carlos Nazareth
 
Esquema eletrico kxh30 v1.1 13
Esquema eletrico kxh30 v1.1 13Esquema eletrico kxh30 v1.1 13
Esquema eletrico kxh30 v1.1 13
Luiz Jr
 
BN44-00289A.pdf
BN44-00289A.pdfBN44-00289A.pdf
BN44-00289A.pdf
LiviuLiviu13
 
M61266 Datasheet PDF
M61266 Datasheet PDFM61266 Datasheet PDF
M61266 Datasheet PDF
Datasheet Bank
 
Smd philips-130419134912-phpapp02
Smd philips-130419134912-phpapp02Smd philips-130419134912-phpapp02
Smd philips-130419134912-phpapp02
Andy Jah
 
Listing the Altera and Cypress Obsolete parts
Listing the Altera and Cypress Obsolete partsListing the Altera and Cypress Obsolete parts
Listing the Altera and Cypress Obsolete parts
Seekcomponents
 

Similar to Dr. maryalice stetler stevenson all mrd (20)

Introduction to electrical distribution and control components
Introduction to electrical distribution and control componentsIntroduction to electrical distribution and control components
Introduction to electrical distribution and control components
 
ONEAL+OCM550.pdf
ONEAL+OCM550.pdfONEAL+OCM550.pdf
ONEAL+OCM550.pdf
 
Ciclotron dynamic 12000 h 2ω
Ciclotron   dynamic 12000 h 2ωCiclotron   dynamic 12000 h 2ω
Ciclotron dynamic 12000 h 2ω
 
OptiCal & LUMOS Networks
OptiCal & LUMOS NetworksOptiCal & LUMOS Networks
OptiCal & LUMOS Networks
 
diagrama del modulo y sensores.pdf
diagrama del modulo y sensores.pdfdiagrama del modulo y sensores.pdf
diagrama del modulo y sensores.pdf
 
Sua chua may lanh cua daikin
Sua chua may lanh cua daikinSua chua may lanh cua daikin
Sua chua may lanh cua daikin
 
Diagrama de Tarjeta T-Con
Diagrama de Tarjeta T-ConDiagrama de Tarjeta T-Con
Diagrama de Tarjeta T-Con
 
Arduino mega-schematic
Arduino mega-schematicArduino mega-schematic
Arduino mega-schematic
 
Edu ciaa-nxp pinout-a4_v4r3_es
Edu ciaa-nxp pinout-a4_v4r3_esEdu ciaa-nxp pinout-a4_v4r3_es
Edu ciaa-nxp pinout-a4_v4r3_es
 
ECS H77H2-M4 rA.pptx
ECS H77H2-M4 rA.pptxECS H77H2-M4 rA.pptx
ECS H77H2-M4 rA.pptx
 
LG CRT TV MODEL Ct 21q92ke
LG CRT TV MODEL Ct 21q92keLG CRT TV MODEL Ct 21q92ke
LG CRT TV MODEL Ct 21q92ke
 
Bn44 00645 a+40f5300
Bn44 00645 a+40f5300Bn44 00645 a+40f5300
Bn44 00645 a+40f5300
 
Antibody validation
Antibody validationAntibody validation
Antibody validation
 
SI47XX_Tuner (1).pdf
SI47XX_Tuner (1).pdfSI47XX_Tuner (1).pdf
SI47XX_Tuner (1).pdf
 
Tabela trans smd
Tabela trans smdTabela trans smd
Tabela trans smd
 
Esquema eletrico kxh30 v1.1 13
Esquema eletrico kxh30 v1.1 13Esquema eletrico kxh30 v1.1 13
Esquema eletrico kxh30 v1.1 13
 
BN44-00289A.pdf
BN44-00289A.pdfBN44-00289A.pdf
BN44-00289A.pdf
 
M61266 Datasheet PDF
M61266 Datasheet PDFM61266 Datasheet PDF
M61266 Datasheet PDF
 
Smd philips-130419134912-phpapp02
Smd philips-130419134912-phpapp02Smd philips-130419134912-phpapp02
Smd philips-130419134912-phpapp02
 
Listing the Altera and Cypress Obsolete parts
Listing the Altera and Cypress Obsolete partsListing the Altera and Cypress Obsolete parts
Listing the Altera and Cypress Obsolete parts
 

More from Hitham Esam

Dr. gerald pfister challenges, solutions and innovations in modern flowcyto...
Dr. gerald pfister   challenges, solutions and innovations in modern flowcyto...Dr. gerald pfister   challenges, solutions and innovations in modern flowcyto...
Dr. gerald pfister challenges, solutions and innovations in modern flowcyto...
Hitham Esam
 
Dr. claude lambert challenges, solutions and innovations in modern flowcyto...
Dr. claude lambert   challenges, solutions and innovations in modern flowcyto...Dr. claude lambert   challenges, solutions and innovations in modern flowcyto...
Dr. claude lambert challenges, solutions and innovations in modern flowcyto...
Hitham Esam
 
Dr. adhra al mawali - immunophenotyping and mrd of acute myeloid leukemia
Dr. adhra al mawali - immunophenotyping and mrd of acute myeloid leukemiaDr. adhra al mawali - immunophenotyping and mrd of acute myeloid leukemia
Dr. adhra al mawali - immunophenotyping and mrd of acute myeloid leukemia
Hitham Esam
 
Prof. heba raslan high sensitivity testing for paroxysmal nocturnal hemoglo...
Prof. heba raslan   high sensitivity testing for paroxysmal nocturnal hemoglo...Prof. heba raslan   high sensitivity testing for paroxysmal nocturnal hemoglo...
Prof. heba raslan high sensitivity testing for paroxysmal nocturnal hemoglo...
Hitham Esam
 
Prof. douaa m. sayed validation and verification of flowcytometry areas
Prof. douaa m. sayed   validation and verification of flowcytometry areasProf. douaa m. sayed   validation and verification of flowcytometry areas
Prof. douaa m. sayed validation and verification of flowcytometry areas
Hitham Esam
 
Dr. nahla farahat immunophenotyping of multiple myeloma
Dr. nahla farahat   immunophenotyping of multiple myeloma Dr. nahla farahat   immunophenotyping of multiple myeloma
Dr. nahla farahat immunophenotyping of multiple myeloma
Hitham Esam
 
Dr. maryalice stetler stevenson lymphoma mrd
Dr. maryalice stetler stevenson   lymphoma mrdDr. maryalice stetler stevenson   lymphoma mrd
Dr. maryalice stetler stevenson lymphoma mrd
Hitham Esam
 
Dr. ismail bakash what do you need to build a flowcytometry laboratory
Dr. ismail bakash   what do you need to build a flowcytometry laboratoryDr. ismail bakash   what do you need to build a flowcytometry laboratory
Dr. ismail bakash what do you need to build a flowcytometry laboratory
Hitham Esam
 
Dr. maryalice stetler stevenson b-all mrd
Dr. maryalice stetler stevenson   b-all mrdDr. maryalice stetler stevenson   b-all mrd
Dr. maryalice stetler stevenson b-all mrd
Hitham Esam
 

More from Hitham Esam (9)

Dr. gerald pfister challenges, solutions and innovations in modern flowcyto...
Dr. gerald pfister   challenges, solutions and innovations in modern flowcyto...Dr. gerald pfister   challenges, solutions and innovations in modern flowcyto...
Dr. gerald pfister challenges, solutions and innovations in modern flowcyto...
 
Dr. claude lambert challenges, solutions and innovations in modern flowcyto...
Dr. claude lambert   challenges, solutions and innovations in modern flowcyto...Dr. claude lambert   challenges, solutions and innovations in modern flowcyto...
Dr. claude lambert challenges, solutions and innovations in modern flowcyto...
 
Dr. adhra al mawali - immunophenotyping and mrd of acute myeloid leukemia
Dr. adhra al mawali - immunophenotyping and mrd of acute myeloid leukemiaDr. adhra al mawali - immunophenotyping and mrd of acute myeloid leukemia
Dr. adhra al mawali - immunophenotyping and mrd of acute myeloid leukemia
 
Prof. heba raslan high sensitivity testing for paroxysmal nocturnal hemoglo...
Prof. heba raslan   high sensitivity testing for paroxysmal nocturnal hemoglo...Prof. heba raslan   high sensitivity testing for paroxysmal nocturnal hemoglo...
Prof. heba raslan high sensitivity testing for paroxysmal nocturnal hemoglo...
 
Prof. douaa m. sayed validation and verification of flowcytometry areas
Prof. douaa m. sayed   validation and verification of flowcytometry areasProf. douaa m. sayed   validation and verification of flowcytometry areas
Prof. douaa m. sayed validation and verification of flowcytometry areas
 
Dr. nahla farahat immunophenotyping of multiple myeloma
Dr. nahla farahat   immunophenotyping of multiple myeloma Dr. nahla farahat   immunophenotyping of multiple myeloma
Dr. nahla farahat immunophenotyping of multiple myeloma
 
Dr. maryalice stetler stevenson lymphoma mrd
Dr. maryalice stetler stevenson   lymphoma mrdDr. maryalice stetler stevenson   lymphoma mrd
Dr. maryalice stetler stevenson lymphoma mrd
 
Dr. ismail bakash what do you need to build a flowcytometry laboratory
Dr. ismail bakash   what do you need to build a flowcytometry laboratoryDr. ismail bakash   what do you need to build a flowcytometry laboratory
Dr. ismail bakash what do you need to build a flowcytometry laboratory
 
Dr. maryalice stetler stevenson b-all mrd
Dr. maryalice stetler stevenson   b-all mrdDr. maryalice stetler stevenson   b-all mrd
Dr. maryalice stetler stevenson b-all mrd
 

Recently uploaded

Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
AnushriSrivastav
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
Rommel Luis III Israel
 
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
ranishasharma67
 
ventilator, child on ventilator, newborn
ventilator, child on ventilator, newbornventilator, child on ventilator, newborn
ventilator, child on ventilator, newborn
Pooja Rani
 
Health Education on prevention of hypertension
Health Education on prevention of hypertensionHealth Education on prevention of hypertension
Health Education on prevention of hypertension
Radhika kulvi
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
Naeemshahzad51
 
Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.
Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.
Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.
preciousstephanie75
 
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
pchutichetpong
 
Myopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptxMyopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptx
RitonDeb1
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Dr. David Greene Arizona
 
Navigating Healthcare with Telemedicine
Navigating Healthcare with  TelemedicineNavigating Healthcare with  Telemedicine
Navigating Healthcare with Telemedicine
Iris Thiele Isip-Tan
 
CONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docxCONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docx
PGIMS Rohtak
 
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
ranishasharma67
 
How many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdfHow many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdf
pubrica101
 
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfCHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
Sachin Sharma
 
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cell
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
The Harvest Clinic
 
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfCHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
Sachin Sharma
 
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
ranishasharma67
 
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
ILC- UK
 

Recently uploaded (20)

Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
 
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
 
ventilator, child on ventilator, newborn
ventilator, child on ventilator, newbornventilator, child on ventilator, newborn
ventilator, child on ventilator, newborn
 
Health Education on prevention of hypertension
Health Education on prevention of hypertensionHealth Education on prevention of hypertension
Health Education on prevention of hypertension
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
 
Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.
Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.
Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.
 
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
 
Myopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptxMyopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptx
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
 
Navigating Healthcare with Telemedicine
Navigating Healthcare with  TelemedicineNavigating Healthcare with  Telemedicine
Navigating Healthcare with Telemedicine
 
CONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docxCONSTRUCTION OF TEST IN MANAGEMENT .docx
CONSTRUCTION OF TEST IN MANAGEMENT .docx
 
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
 
How many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdfHow many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdf
 
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfCHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
 
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptx
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
 
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfCHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
 
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
 
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
 

Dr. maryalice stetler stevenson all mrd

  • 1. B-ALL MRD Maryalice Stetler-Stevenson, M.D., Ph.D. Flow Cytometry Unit, Laboratory of Pathology, CCR, NCI, NIH DEPARTMENT OF HEALTH & HUMAN SERVICES National Instit Bethesda, M Public Health
  • 2. FL1 FL2 FL4 FL5 FL6 FL8 FITC PE Per CP- Cy5.5 PC7 APC APC-Cy7 or APC-H7 Tube 1 CD20 CD10 CD38* CD19 CD58 CD45* B9E9 J5 HIT2 J3-119 N901 2D1 3ml 10ml 5ml 3ml 10ml 3ml Tube 2 CD9 CD13/ CD33 CD34* CD19 CD10* CD45* ALB6 SJ1D1 /D3HL60.2 51 8G12 J3-119 HI10a 2D1 3ml 5ml / 10ml 15ml 3ml 3ml 3ml Tube 3 Syto-16 CD3* CD19 CD71* CD45* S7578 SK7 J3-119 L10.1 2D1 1ml 10ml 3ml 5ml 3ml The COG Assay Panel
  • 3. The COG Gating Strategy for B-ALL MRD: Time FSC-A 0 12500 2500 0 37500 5 0000 0 65536 13 1072 19 6608 26 2144 Time 8color CD19 PC7 SSC-A 10 2 10 3 10 4 10 5 0 65 536 131 072 196 608 262 144 FSC-A SSC-A 0 65536 131072 1966 08 262144 0 65536 1310 72 1966 08 2621 44 CD45 AH7 CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 FSC-A FSC-H 0 65536 1 31072 196608 262 144 0 65536 131072 196608 262144 SINGLETS
  • 4. Case 1 SF15 1185 bm_06_L-3.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF15 1185 bm_04_L-1.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF15 1185 bm_05_L-2.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF15 1185 bm_01_S-1.fcs Time 8color FSC-A FSC-H 0 6 5536 131072 196608 26214 4 0 6 5536 1 3107 2 1 9660 8 2 6214 4 SINGLETS SF15 1185 7aad9_viability.fcs Viability Singlets 7AAD SSC-A 10 2 10 3 10 4 10 5 0 65 536 1 310 72 1 966 08 2 621 44 7aad SSC Viable 7AAD Gate % of Gated Cells None 100 7aad SSC 97 SF15 1185 bm_01_S-1.fcs SINGLETS FSC-A SSC-A 0 65 536 131072 1966 08 26 2144 0 65536 1 3107 2 1 9660 8 2 6214 4 SF15 1185 bm_04_L-1.fcs SINGLETS CD19 PC7 SSC-A 10 2 10 3 10 4 10 5 0 65536 131072 196608 262144 SF15 1185 bm_04_L-1.fcs 8c B CD19 PC7 SSC CD45 AH7 CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Clean L1 gate SF15 1185 bm_05_L-2.fcs 8c B CD19 PC7 SSC CD45 AH7 CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5
  • 5. Quadrant # of Events % of Gated Cells % of All Cells UL 90199 16.65 9.02 UR 613 0.11 0.06 LL 305369 56.37 30.54 LR 145532 26.87 14.55 Gate # of Events % of Gated Cells % of All Cells None 906160 100.00 90.62 Syto 16 positive 906160 100.00 90.62 Syto16 MNC 541713 59.78 54.17 Syto16 + Syto16 + MNC Case 1 SF15 1185 bm_06_L-3.fcs Syto 16 positive Syto 16 SSC-A 10 2 10 3 10 4 10 5 0 65536 131072 196608 262144 Syto 16 positive SF15 1185 bm_06_L-3.fcs Syto16 MNC CD3 PerCP CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 16.65% 0.11% 56.37% 26.87% SF15 1185 bm_06_L-3.fcs Syto 16 positive FSC-A SSC-A 26 65556 131085 196615 262144 0 65536 1310 72 1966 08 2621 44 Syto16 MNC SF15 1185 bm_06_L-3.fcs Syto 16 positive CD3 PerCP CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 16.55%73.09% 0.09%10.27%
  • 6. SF15 1185 bm_04_L-1.fcs Clean L1 gate CD19 PC7 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_04_L-1.fcs Clean L1 gate CD10 PE CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_04_L-1.fcs Clean L1 gate CD45 AH7 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_04_L-1.fcs Clean L1 gate CD20 FITC CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Case 1 SF15 1185 bm_04_L-1.fcs Clean L1 gate CD45 AH7 CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_04_L-1.fcs Clean L1 gate CD38 PerCP Cy55 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_04_L-1.fcs Clean L1 gate CD20 FITC CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_04_L-1.fcs Clean L1 gate CD45 AH7 CD20FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_04_L-1.fcs Clean L1 gate CD20 FITC CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 L1 Plasma cells? SF15 1185 bm_04_L-1.fcs Clean L1 gate CD20 FITC CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate 1 L1 1.10% SF15 1185 bm_04_L-1.fcs Clean L1 gate CD45 AH7 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_04_L-1.fcs Clean L1 gate CD38 PerCP Cy55 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_04_L-1.fcs Clean L1 gate CD19 PC7 CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_04_L-1.fcs Clean L1 gate CD19 PC7 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate # of Events % of Gated Cells % of All Cells None 76867 100.00 7.69 8c B CD19 PC7 76867 100.00 7.69 Clean L1 gate 76867 100.00 7.69 Gate 1 L1 845 1.10 0.08
  • 7. Case 1 SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD19 PC7 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD9 FITC CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 % of L-22 Cells ALL= % of L-22 MNC ALL= SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD34 PerCP Cy55 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD10 APC CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD45 AH7 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD34 PerCP Cy55 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD19 PC7 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD34 PerCP Cy55 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD13+33 PE CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD45 AH7 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD19 PC7 CD34PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD45 AH7 CD34PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD19 PC7 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate 2 L1 0.88% SF15 1185 bm_05_L-2.fcs Clean L2 Gate CD45 AH7 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate # of Events % of Gated Cells % of All Cells None 91625 100.00 9.16 8c B CD19 PC7 91625 100.00 9.16 Clean L2 Gate 91625 100.00 9.16 Gate 2 L1 806 0.88 0.08
  • 8. Case 1 Tube 1: 845 x 90,199 x 100= 0.18 76,867 541,713 Tube 2: 806 x 90,199 x 100= 0.15 91,625 541,713
  • 9. Case 2 SF15 657 7aad_viability.fcs No Gate Time FSC-A 0 5000 10000 15000 20000 0 65536 131072 196608 262144 Time 4color SF15 657 bm_07_L-3.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF15 657 bm_05_L-1.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF15 657 bm_06_L-2.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF15 657 bm_05_L-1.fcs 8c B CD19 PC7 SSC CD45 AH7 CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Clean L1 gate SF15 657 bm_05_L-1.fcs SINGLETS CD19 PC7 SSC-A 10 2 10 3 10 4 10 5 0 65536 131072 196608 262144 SF15 657 bm_01_S-1.fcs Time 8color FSC-A FSC-H 0 65536 131072 196608 262144 0 65536 131072 196608 262144 SINGLETS SF15 657 bm_01_S-1.fcs Time 8color FSC-A FSC-W 0 65536 131072 196608 262144 0 65536 131072 196608 262144 SF15 657 7aad_viability.fcs Viability Singlets 7AAD SSC-A 10 2 10 3 10 4 10 5 0 65536 131072 196608 262144 7AAD 7aad SSC Viable Gate % of Gated Cells None 100 7aad SSC 89 SF15 657 bm_01_S-1.fcs SINGLETS FSC-A SSC-A 0 65536 131072 196608 262144 0 65536 131072 196608 262144
  • 10. Case 2 SF15 657 bm_05_L-1.fcs Clean L1 gate CD38 PerCP Cy55 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_05_L-1.fcs Clean L1 gate CD20 FITC CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_05_L-1.fcs Clean L1 gate CD10 PE CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_05_L-1.fcs Clean L1 gate CD38 PerCP Cy55 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_05_L-1.fcs Clean L1 gate CD45 AH7 CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_05_L-1.fcs Clean L1 gate CD45 AH7 CD20FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_05_L-1.fcs Clean L1 gate CD45 AH7 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate 1 L1 2.55% SF15 657 bm_05_L-1.fcs Clean L1 gate CD20 FITC CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_05_L-1.fcs Clean L1 gate CD20 FITC CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate # of Events % of Gated Cells % of All Cells None 47182 100.00 4.72 8c B CD19 PC7 47182 100.00 4.72 Clean L1 gate 47182 100.00 4.72 Gate 1 L1 1205 2.55 0.12 SF15 657 bm_05_L-1.fcs Clean L1 gate CD20 FITC CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_05_L-1.fcs Clean L1 gate CD19 PC7 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_05_L-1.fcs Clean L1 gate CD19 PC7 CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_05_L-1.fcs Clean L1 gate CD19 PC7 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_05_L-1.fcs Clean L1 gate CD45 AH7 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5
  • 11. SF15 657 bm_06_L-2.fcs Clean L2 Gate CD10 APC CD34PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_06_L-2.fcs Clean L2 Gate CD19 PC7 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Case 2 SF15 657 bm_06_L-2.fcs Clean L2 Gate CD45 AH7 CD34PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_06_L-2.fcs Clean L2 Gate CD19 PC7 CD34PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_06_L-2.fcs Clean L2 Gate CD45 AH7 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate 1 L2 2.57% SF15 657 bm_06_L-2.fcs Clean L2 Gate CD34 PerCP Cy55 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_06_L-2.fcs Clean L2 Gate CD13+33 PE CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_06_L-2.fcs Clean L2 Gate CD34 PerCP Cy55 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_06_L-2.fcs Clean L2 Gate CD19 PC7 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_06_L-2.fcs Clean L2 Gate CD19 PC7 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate # of Events % of Gated Cells % of All Cells None 44447 100.00 4.44 Clean L2 44447 100.00 4.44 Gate 1 L2 1141 2.57 0.11 SF15 657 bm_06_L-2.fcs Clean L2 Gate CD10 APC CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_06_L-2.fcs Clean L2 Gate CD19 PC7 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_06_L-2.fcs Clean L2 Gate CD10 APC CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 657 bm_06_L-2.fcs Clean L2 Gate CD45 AH7 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5
  • 12. Case 2 SF15 657 bm_07_L-3.fcs Syto 16 positive Syto 16 SSC-A 10 2 10 3 10 4 10 5 0 65 536 13 1 07 2 19 6 60 8 26 2 14 4 Syto 16 positive SF15 657 bm_07_L-3.fcs Syto16 MNC CD3 PerCP CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 8.24%39.24% 0.09%52.43% SF15 657 bm_07_L-3.fcs Syto 16 positive FSC-A SSC-A 26 65556 131085 196615 262144 0 65536 1 31072 1 96608 2 62144 Syto16 MNC SF15 657 bm_07_L-3.fcs Syto 16 positive CD3 PerCP CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 5.75% 0.04% 91.58% 2.62% Quadrant # of Events Y Geometric Mean % of Gated Cells % of All Cells UL 43565 7998.77 52.43 4.36 UR 75 4515.68 0.09 0.01 LL 32601 0.00 39.24 3.26 LR 6848 0.00 8.24 0.68 Gate # of Events % of Gated Cells % of All Cells None 850029 100.00 85.00 Syto 16 positive 850029 100.00 85.00 Syto16 MNC 83089 9.77 8.31
  • 13. Case 2 Tube 1: 1,205 x 43,565 x 100= 1.34 47,182 83,089 Tube 2: 1,141 x 43,565 x 100= 1.35 44,447 83,089
  • 14. Case 3 SF15 2200 bm 7aad_viability.fcs No Gate Time FSC-A 0 5000 10000 15000 20000 0 65536 131072 196608 262144 Time 4color SF15 2200 bm_05_L-3.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF15 2200 bm_03_L-1.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF15 2200 bm_04_L-2.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF15 2200 bm_01_S-1.fcs Time 8color FSC-A FSC-H 0 65 536 131 072 19 660 8 2 62144 0 6 55 36 131 0 72 196 6 08 262 1 44 SINGLETS SF15 2200 bm_01_S-1.fcs Time 8color FSC-A FSC-W 0 6 5 536 131 072 19 6608 2 62144 0 655 36 1310 7 2 1966 0 8 2621 4 4 SF15 2200 bm 7aad_viability.fcs Viability Singlets 7AAD SSC-A 10 2 10 3 10 4 10 5 0 65 5 36 13 1 072 19 6 608 26 2 144 7aad SSC Viable 7AAD Gate % of Gated Cells None 100 7aad SSC 86 SF15 2200 bm_03_L-1.fcs 8c B CD19 PC7 SSC CD45 AH7 CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Clean L1 gate SF15 2200 bm_03_L-1.fcs SINGLETS CD19 PC7 SSC-A 10 2 10 3 10 4 10 5 0 6553 6 1 310 7 2 1 966 0 8 2 621 4 4
  • 15. Gate # of Events % of Gated Cells % of All Cells None 4735 100.00 0.55 8c B CD19 PC7 4735 100.00 0.55 Clean L1 gate 4735 100.00 0.55 Gate 1.L1 180 3.80 0.02 Case 3 SF15 2200 bm_03_L-1.fcs Clean L1 gate CD45 AH7 CD20FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_03_L-1.fcs Clean L1 gate CD20 FITC CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_03_L-1.fcs Clean L1 gate CD20 FITC CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_03_L-1.fcs Clean L1 gate CD20 FITC CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 L1 Plasma cells? SF15 2200 bm_03_L-1.fcs Clean L1 gate CD20 FITC CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_03_L-1.fcs Clean L1 gate CD45 AH7 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_03_L-1.fcs Clean L1 gate CD19 PC7 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_03_L-1.fcs Clean L1 gate CD45 AH7 CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_03_L-1.fcs Clean L1 gate CD38 PerCP Cy55 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_03_L-1.fcs Clean L1 gate CD45 AH7 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate 1.L1 SF15 2200 bm_03_L-1.fcs Clean L1 gate CD10 PE CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_03_L-1.fcs Clean L1 gate CD19 PC7 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_03_L-1.fcs Clean L1 gate CD38 PerCP Cy55 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_03_L-1.fcs Clean L1 gate CD19 PC7 CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5
  • 16. SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD45 AH7 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD19 PC7 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Case 3 SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD19 PC7 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD10 APC CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD19 PC7 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD34 PerCP Cy55 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD9 FITC CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 % of L-22 Cells ALL= % of L-22 MNC ALL= SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD45 AH7 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD34 PerCP Cy55 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD13+33 PE CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD34 PerCP Cy55 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD45 AH7 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD19 PC7 CD34PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2200 bm_04_L-2.fcs Clean L2 Gate CD45 AH7 CD34PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate # of Events % of Gated Cells % of All Cells None 4485 100.00 0.57 8c B CD19 PC7 4485 100.00 0.57 Gate 1.L2 170 3.79 0.02 Clean L2 Gate 4485 100.00 0.57
  • 17. Case 3 SF15 2200 bm_05_L-3.fcs Syto16 MNC CD3 PerCP CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 6.10% 0.14% 64.89% 28.88% SF15 2200 bm_05_L-3.fcs Syto 16 positive FSC-A SSC-A 26 655 56 1 31 08 5 19 66 15 2 6214 4 0 65 53 6 1 31 072 1 96 608 2 62 144 Syto16 MNC SF15 2200 bm_05_L-3.fcs Syto 16 positive CD3 PerCP CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 7.55%91.34% 0.44%0.68% Quadrant # of Events % of Gated Cells % of All Cells UL 5335 6.10 0.53 UR 121 0.14 0.01 LL 56778 64.89 5.68 LR 25271 28.88 2.53 Gate # of Events % of Gated Cells % of All Cells None 826111 100.00 82.61 Syto 16 positive 826111 100.00 82.61 Syto16 MNC 87505 10.59 8.75 SF15 2200 bm_05_L-3.fcs Syto 16 positive Syto 16 SSC-A 10 2 10 3 10 4 10 5 0 65536 131072 196608 262144 Syto 16 positive
  • 18. Case 3 Tube 1: 180 x 5,335 x 100= 0.23 4,735 87,505 Tube 2: 170 x 5,335 x 100= 0.23 4,485 87,505
  • 19. Case 4 SF15 2455 7aad_viability.fcs No Gate Time FSC-A 0 5000 10000 15000 20000 0 65536 131072 196608 262144 Time 4color SF15 2455 bm_06_L-3.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF15 2455 bm_04_L-1.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF15 2455 bm_05_L-2.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF15 2455 bm_01_S-1.fcs Time 8color FSC-A FSC-H 0 65536 131072 196608 262144 0 65536 131072 196608 262144 SINGLETS SF15 2455 bm_01_S-1.fcs Time 8color FSC-A FSC-W 0 65536 131072 196608 262144 0 65536 131072 196608 262144F15 2455 7aad_viability.fcs Viability Singlets 7AAD SSC-A 10 2 10 3 10 4 10 5 0 65536 131072 196608 262144 7AAD 7aad SSC Viable Gate % of Gated Cells None 100 7aad SSC Viable 93 SF15 2455 bm_01_S-1.fcs SINGLETS FSC-A SSC-A 0 65536 131072 196608 262144 0 65536 131072 196608 262144 SF15 2455 bm_04_L-1.fcs 8c B CD19 PC7 SSC CD45 AH7 CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Clean L1 gate SF15 2455 bm_04_L-1.fcs SINGLETS CD19 PC7 SSC-A 10 2 10 3 10 4 10 5 0 65 536 131072 196608 262144
  • 20. Case 4 SF15 2455 bm_04_L-1.fcs Clean L1 gate CD19 PC7 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_04_L-1.fcs Clean L1 gate CD20 FITC CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_04_L-1.fcs Clean L1 gate CD20 FITC CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_04_L-1.fcs Clean L1 gate CD20 FITC CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 L1 Plasma cells? SF15 2455 bm_04_L-1.fcs Clean L1 gate CD20 FITC CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_04_L-1.fcs Clean L1 gate CD45 AH7 CD20FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_04_L-1.fcs Clean L1 gate CD38 PerCP Cy55 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_04_L-1.fcs Clean L1 gate CD10 PE CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_04_L-1.fcs Clean L1 gate CD38 PerCP Cy55 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_04_L-1.fcs Clean L1 gate CD45 AH7 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_04_L-1.fcs Clean L1 gate CD19 PC7 CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_04_L-1.fcs Clean L1 gate CD45 AH7 CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_04_L-1.fcs Clean L1 gate CD19 PC7 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_04_L-1.fcs Clean L1 gate CD45 AH7 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate # of Events % of Gated Cells % of All Cells None 3518 100.00 0.35 8c B CD19 PC7 3518 100.00 0.35 Clean L1 gate 3518 100.00 0.35 Gate 1.L1 1331 37.83 0.13
  • 21. Case 4 Gate # of Events % of Gated Cells % of All Cells None 4582 100.00 0.46 8c B CD19 PC7 4582 100.00 0.46 Gate 1.L2 2557 55.81 0.26 Clean L2 Gate 4582 100.00 0.46 SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD45 AH7 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD45 AH7 CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD45 AH7 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD34 PerCP Cy55 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD19 PC7 CD34PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD45 AH7 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate 1.L2 55.81% SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD13+33 PE CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD34 PerCP Cy55 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD19 PC7 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD45 AH7 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD10 APC CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD34 PerCP Cy55 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD10 APC CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 % of L-22 Cells ALL= % of L-22 MNC ALL= SF15 2455 bm_05_L-2.fcs Clean L2 Gatee CD19 PC7 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5
  • 22. Case 4 SF15 2455 bm_06_L-3.fcs Syto 16 positive Syto 16 SSC-A 10 2 10 3 10 4 10 5 0 65536 131072 196608 262144 Syto 16 positive SF15 2455 bm_06_L-3.fcs Syto16 MNC CD3 PerCP CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 16.59%81.40% 0.06%1.94% SF15 2455 bm_06_L-3.fcs Syto 16 positive FSC-A SSC-A 26 6 5556 13 1085 196615 262 144 0 655 36 131072 196608 262144 Syto16 MNC SF15 2455 bm_06_L-3.fcs Syto 16 positive CD3 PerCP CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 0.54% 0.09% 91.81% 7.57% Quadrant # of Events % of Gated Cells % of All Cells UL 4588 1.94 0.46 UR 152 0.06 0.02 LL 192527 81.40 19.25 LR 39240 16.59 3.92 Gate # of Events % of Gated Cells % of All Cells None 877716 100.00 87.77 Syto 16 positive 877716 100.00 87.77 Syto16 MNC 236507 26.95 23.65
  • 23. Case 4 Tube 1: 1331 x 4588 x 100= 0.73 3518 236507 Tube 2: 2557 x 4588 x 100= 1.1 4582 236507 Which tube had better isolation of ALL from Normal?
  • 24. Case 5 SF16 043 7aad_viability.fcs No Gate Time FSC-A 0 5000 10000 15000 20000 0 65536 131072 196608 262144 Time 4color SF16 043 bm_06_L-3_003.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF16 043 bm_04_L-1_001.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF16 043 bm_05_L-2_002.fcs No Gate Time FSC-A 0 12500 25000 37500 50000 0 65536 131072 196608 262144 Time 8color SF16 043 bm_01_S-1_002.fcs Time 8color FSC-A FSC-H 0 65536 1310 72 19 6608 26214 4 0 65536 131072 196608 262144 SINGLETS SF16 043 bm_01_S-1_002.fcs Time 8color FSC-A FSC-W 0 65536 1310 72 19 6608 2 62144 0 65536 131072 196608 262144F16 043 7aad_viability.fcs Viability Singlets 7AAD SSC-A 10 2 10 3 10 4 10 5 0 65 536 13 107 2 19 660 8 26 214 4 7AAD 7aad SSC Viable Gate % of Gated Cells None 100 7aad SSC Viable 93 SF16 043 bm_01_S-1_002.fcs Time 8color FSC-A SSC-A 0 65536 13107 2 19 660 8 262 14 4 0 65 53 6 1 31 07 2 1 96 60 8 2 62 14 4 SF16 043 bm_04_L-1_001.fcs 8c B CD19 PC7 SSC CD45 AH7 CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Clean L1 gate SF16 043 bm_04_L-1_001.fcs SINGLETS CD19 PC7 SSC-A 10 2 10 3 10 4 10 5 0 65 536 131072 196608 262144
  • 25. Case 5 SF16 043 bm_06_L-3_003.fcs Syto 16 positive Syto 16 SSC-A 10 2 10 3 10 4 10 5 0 65 536 131 072 196 608 262 144 Syto 16 positive SF16 043 bm_06_L-3_003.fcs Syto16 MNC CD3 PerCP CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 25.93%44.99% 0.08%29.00% SF16 043 bm_06_L-3_003.fcs Syto 16 positive FSC-A SSC-A 26 65 556 13 10 8 5 1 9 6615 2 62 1 44 0 65 5 36 1 310 72 1 966 08 2 621 44 Syto16 MNC SF16 043 bm_06_L-3_003.fcs Syto 16 positive CD3 PerCP CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 5.91% 0.11% 86.68% 7.30% Quadrant # of Events % of Gated Cells % of All Cells UL 47936 29.00 4.79 UR 140 0.08 0.01 LL 74375 44.99 7.44 LR 42872 25.93 4.29 Gate # of Events % of Gated Cells % of All Cell s None 977423 100 98 Syto 16 positive 886478 91 89 Syto16 MNC 165323 17 17
  • 26. Case 5 SF16 043 bm_04_L-1_001.fcs Clean L1 gate CD20 FITC CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_04_L-1_001.fcs Clean L1 gate CD20 FITC CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_04_L-1_001.fcs Clean L1 gate CD20 FITC CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 L1 Plasma cells? SF16 043 bm_04_L-1_001.fcs Clean L1 gate CD20 FITC CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_04_L-1_001.fcs Clean L1 gate CD45 AH7 CD20FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_04_L-1_001.fcs Clean L1 gate CD19 PC7 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_04_L-1_001.fcs Clean L1 gate CD38 PerCP Cy55 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_04_L-1_001.fcs Clean L1 gate CD10 PE CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_04_L-1_001.fcs Gate 7 CD45 AH7 CD10PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_04_L-1_001.fcs Clean L1 gate CD19 PC7 CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_04_L-1_001.fcs Clean L1 gate CD38 PerCP Cy55 CD19PC7 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_04_L-1_001.fcs Gate 7 CD45 AH7 CD38PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate 1.L1 2.08% SF16 043 bm_04_L-1_001.fcs Clean L1 gate CD19 PC7 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_04_L-1_001.fcs Clean L1 gate CD45 AH7 CD58APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate # of Events % of Gated Cells None 49767 100.00 8c B CD19 PC7 49767 100.00 Clean L1 gate 49767 100.00 Gate 1.L1 1111 2.23
  • 27. SF16 043 bm_05_L-2_002.fcs Clean L2 Gate CD45 AH7 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_05_L-2_002.fcs Clean L2 Gate CD19 PC7 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_05_L-2_002.fcs Clean L2 Gate CD45 AH7 CD34PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Case 5 L-2 9 13+33 34 19 10 45 SF16 043 bm_05_L-2_002.fcs Clean L2 Gate CD19 PC7 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_05_L-2_002.fcs Gate 9 CD9 FITC CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 % of L-22 Cells ALL= % of L-22 MNC ALL= SF16 043 bm_05_L-2_002.fcs Clean L2 Gate CD34 PerCP Cy55 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_05_L-2_002.fcs Clean L2 Gate CD10 APC CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_05_L-2_002.fcs Clean L2 Gate CD19 PC7 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_05_L-2_002.fcs Clean L2 Gate CD45 AH7 CD9FITC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_05_L-2_002.fcs Clean L2 Gate CD34 PerCP Cy55 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_05_L-2_002.fcs Clean L2 Gate CD13+33 PE CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_05_L-2_002.fcs Clean L2 Gate CD34 PerCP Cy55 CD10APC 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_05_L-2_002.fcs Clean L2 Gate CD45 AH7 CD13+33PE 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 SF16 043 bm_05_L-2_002.fcs Clean L2 Gate CD19 PC7 CD34PerCPCy55 10 2 10 3 10 4 10 5 10 2 10 3 10 4 10 5 Gate # of Events % of Gated Cells % o All Cel None 42549 100.00 4.2 8c B CD19 PC7 42549 100.00 4.2 Gate 1.L2 918 2.16 0.0 Clean L2 Gate 42549 100.00 4.2
  • 28. Case 5 Tube 1: 1111 x 47936 x 100= 0.65 49767 165323 Tube 2: 918 x 47936 x 100= 0.63 42549 165323
  • 29. Remember Typical Analysis Errors: Miscalling hematogones Overly tight gating, especially initial B cell gate Lack of hierarchical gating Artifacts and normal variants

Editor's Notes

  1. <number>